四环医药(00460.HK)中期由亏转盈1.7亿元 研发投入升43.9% 每股派息3.1分
格隆汇8月25日丨四环医药(00460.HK)公告,截至2020年6月30日止6个月,公司收益达10.55亿元人民币,公司拥有人应占溢利1.7亿元,上年同期亏损20亿元;每股盈利1.8分,每股中期现金股息0.1分及每股特别现金股息3分。
集团继续进行研究及开发活动。研发投入及相关活动上升43.9%至约人民币3.93亿元,占集团总收益的37.2%。
于2020年6月30日,集团维持稳健的财务状况,并录得约人民币43.36亿元净现金。集团的负债与权益比率为7.1%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.